AstraZeneca Pharmaceuticals LP
NEWS
A final analysis of AstraZeneca’s Phase III POSEIDON trial shows IMFINZI (durvalumab), offered improvements in overall survival (OS) when added to tremelimumab and chemotherapy versus chemotherapy alone in patients with Stage IV (metastatic) non-small cell lung cancer.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 4, 2021.
The regulatory nod marks the first time the FDA approved an SGLT2 inhibitor for the treatment of CKD regardless of diabetes status.
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.
Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications.
AstraZeneca’s COVID-19 vaccine road to approval has been anything but smooth.
AstraZeneca reported its first-quarter financial reports. As is often the case, they updated their pipeline, and indicated they had dropped a few drugs, including a promising multiple myeloma drug.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 27, 2021.
A new study published online has provided some hope for the citizens in India, with researchers suggesting that the Covaxin vaccine, developed by Bharat Biotech and Pennsylvania-based Ocugen, could neutralize the SARS-CoV-2 variant leading the second wave in the country.
JOBS
IN THE PRESS